Tatjana Seidens

Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib

Sean M. Grimmond, Peter T. Simpson, Georgia Chenevix-Trench, 2015, PloS one.

Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women

S. Fox, A. Vargas, S. Lakhani, 2013, Breast Cancer Research and Treatment.